StockWatch
·
IND-SWIFT LABORATORIES LTD. · QQ2 FY-2027 · THE CALL

Execution-led growth on track; margin recovery delayed to H2

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsINDSWFTLABIND-SWIFT LABORATORIES LTD.10 Nov 2026 · 6 min read
Verdict

Buy

confidence 7/10

Credibility

Grade B

Hit FY27 >50% revenue growth; CDMO ₹100 Cr H1 on ₹130 track. Margin target (18% sustainable, 21-22% by H2) partially missed; next-quarter guidance 19-20% below internal 22% but not formally withdrawn.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Revenue growth exceptional (57.5% YoY, 328% PAT growth) with clear CDMO partnerships (Viatris, others) and territory expansion fueling FY30 ₹1,500 Cr vision. Near-term risk: margins compressed at 18.7% OPM vs 18% target, Q3-Q4 guidance 19-20% vs 22% internal target signals execution slippage despite strong top-line.

₹240.5 Cr

Revenue · +57.5% YoY

₹undefined Cr

Reported PAT · +328.3% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Operating leverage and margin expansion

OVERSTATED

OPM 18.7%, below 18% sustainable target; next quarter guidance 19-20% vs 22% internal target

More than 50% revenue growth FY27

MET

Q2 YoY +57.5%, corroborates guidance

FY30 ₹1,500 Cr revenue with ₹200+ Cr PAT

MET

Prior guidance reaffirmed, not withdrawn; no explicit upgrade this call

EBITDA margins 21-22% by H2 FY27

MISS

Q3-Q4 guidance 19-20%, below prior target; near-term hedging evident

₹100-130 Cr CDMO revenue FY27

MET

H1 done ₹100 Cr (Q1 ₹15 Cr + Q2 ₹65 Cr CDMO); trajectory supports ₹130+ by year-end

Earnings quality

What changed since the last call

Deltas vs. the prior call

Margin timing reset lower

Downgrade

Prior (Q1 call): 21-22% EBITDA target by H2 FY27. This call Q3-Q4 guidance: 19-20%. Delivered Q2 at 17.97%, below 18% sustainable.

FY28 guidance to be revised

New

Gagan: 'For FY28, whatever guidance we have given, I think we might revise this and the numbers might increase.' Explicit signal FY28 prior guidance too conservative.

CDMO mix acceleration

Upgrade

Q1 ₹15 Cr → Q2 ₹65 Cr CDMO revenue; Atorvastatin+Ezetimibe ₹58 Cr Q2 vs ₹25 Cr Q1 (+132% QoQ). Exceeds prior trajectory expectations.

Facility approval timelines uncertain

Neutral

Samba EU-GMP/PIC/S approval awaited (ANVISA Brazil focus), Derassi warehouse shift 10-12 months, Clarithromycin variation batches pending. Timing not committed.

The Q&A

Analysts pressed on margin trajectory (Gaurav Shukla, Zaki Nasser, Vikas Rohira) — management held firm on 20% full-year target but hedged Q3-Q4 at 19-20%, acknowledging execution risk. Capex details (Shiladitya Choudhury) deferred to ConfidLeap. Management candid on Viatris dependency (Meet Gada) and CDMO volume constraints, but confident in new customer wins (₹80-90 Cr from new customers FY27).

The exchanges that mattered

H2 revenue & margin trajectory — Gaurav Shukla, ICICI Bank

Partial

Guidance >50% delivered in H1. H2 revenue expected to continue growth; margins next quarter 19-20%, then recovery. Internal target 22% for full year.

CDMO business growth — Aaryan Bhatia, analyst

Answered

Q1 ₹15 Cr, Q2 ₹65 Cr. Quarterly run-rate will increase. Ibuprofen Q3 ₹20-25 Cr, Atorvastatin+Ezetimibe ₹58 Cr Q2 vs ₹25 Cr Q1. Growth from 2 key molecules, better than anticipated.

Ibuprofen market positioning — Meet Gada, analyst

Answered

Quantities agreed with Viatris; they drive end-sales globally. We manufacture on their behalf. Defined transfer pricing. Established, steadily growing molecule. Product registration 1-1.5 years, commercial revenue generation year two.

Facility capacity utilization — Gaurav Shukla, ICICI Bank

Answered

Currently 70-75% utilized at Jammu/Samba. Capex underway, EU-GMP/PIC/S approval expected next year. Facility target export-only. Land acquired, construction started.

Derassi warehouse shift — Vishnu Agarwal, analyst

Answered

Land acquired, requisite approvals in place, construction started. Shift expected 10-12 months. Will support ₹1,200 Cr revenue reach by FY28.

Clarithromycin launch timing — Gaurav Shukla, ICICI Bank

Partial

Customer filed variation in Europe. As soon as approval, batches will initiate. Currently awaiting site variation approval.

FY30 revenue guidance — Zaki Nasser, analyst

Dodged

Very difficult to comment on March '28 at this juncture. Next investor call, ready with FY28 numbers. Fingers crossed. ₹1,000 Cr with 20% EBITDA is minimum internal target given to entire team.

Synthimed stake monetization — Zaki Nasser, analyst

Partial

IndiaRF holds majority. Diligences happening; they want off some stake. Informed investors we tag along. Board will decide participation. Business valued ₹7,000-8,000 Cr; may monetize some portion in coming quarters.

API sourcing concentration — Varun Nagpal, analyst

Answered

Majority of key starting materials/APIs from Synthimed. China limited to 1-2 molecules. Total purchases from Synthimed ~₹100 Cr of ~₹400 Cr total raw material procurement.

New customer wins — Gaurav Shukla, ICICI Bank

Answered

Normally prepare data molecule-wise. On new customers, ₹80-90 Cr this year from newly acquired customers.

R&D pipeline — Aaryan Bhatia, analyst

Answered

Not planning complex formulations entry. Focus more on where we get good EBITDA margins. 11 molecules at different R&D stages shared in presentation. Forward pipeline FY28-FY29 ready; FY29-FY30 have two molecules. Growth in FY28 from ramp-up of existing pipeline/approved molecules.

Working capital requirement — Vijay Soni, analyst

Answered

If ₹1,500 Cr turnover by FY30, working capital requirement ~₹350 Cr. Average realization cycle 75 days. Collection target ~60 days. Inventory target minimum 90 days.

EBITDA margin 20% sustainability — Vikas Rohira, analyst

Partial

In past, tried to maintain whatever achieved. Management determined and focused on achieving 20% EBITDA margin target for full year.

Competition in new markets — Aaryan Bhatia, analyst

Answered

Ethical sales approach, established molecules, built 2006. Established distributors, local teams, competitive pricing. In regulated markets, not competing with innovators (CDMO advantage). Long-standing brand presence provides differentiation.

Guidance

Forward guidance and management's confidence

FY27 >50% revenue growth (from FY26 ₹~152 Cr base implied)

High

Already delivered 57.5% YoY growth in Q2. Q1-Q2 pacing well. Sequential momentum into H2.

₹1,200-1,250 Cr by March 2028 (FY28)

Medium

Derassi capacity target ₹1,200 Cr. Ibuprofen, Macrogol ramp + new customers ₹80-90 Cr. Facility approvals timing uncertain.

₹1,500+ Cr by FY30 with 200-300 bps EBITDA margin expansion

Medium

FY27 base ~₹750-1000 Cr implied; CAGR ~27% to FY30. Funded by CDMO scaling, new territories. Margin expansion from scale leverage.

EBITDA margin 18% sustainable (from prior Q1 call guidance)

Low

Q2 delivered 17.97%, below 18%. Next quarter 19-20% guidance further downgrades near-term recovery.

22% internal EBITDA margin target for H2 FY27

Low

Gagan confirmed as 'internal target' but Q3-Q4 guidance only 19-20%. Significant miss vs 22%, suggesting hedging or execution risk.

20% EBITDA margin for full FY27

Medium

Q1-Q2 ~20% achieved. Q3-Q4 targeting 19-20%, then recovery into FY28 onwards.

₹250 Cr capex over 2.5 years (from prior guidance)

Medium

Samba EU-GMP/PIC/S (₹45 Cr upgrade), Derassi warehouse (10-12 months), Samba facility expansion. Detailed capex timeline shared via ConfidLeap (deferred from call).

Risks the call surfaced

Ranked by how much they should concern a holder

Customer concentration

High

H1 CDMO ₹100 Cr includes Ibuprofen, Atorvastatin+Ezetimibe, Macrogol from Viatris/Tiefenbacher. Likely >60% of CDMO revenue. Single-customer risk. Viatris drives end-sales globally; volumes subject to their demand.

Margin trajectory

Medium

Q2 EBITDA margin 17.97%, below 18% sustainable target. Next quarter guidance 19-20%, below 22% internal target for H2. Suggests execution pressure, cost inflation, or mix headwinds persisting.

Facility approval delays

Medium

Samba EU-GMP/PIC/S ANVISA approval awaited (Brazil export focus), Derassi warehouse shift 10-12 months (unrealistic timeline may slip). Clarithromycin variation approval pending in Europe. Delays risk FY28 revenue targets.

API sourcing concentration

Medium

Majority of key starting materials/APIs from Synthimed (~₹100 Cr of ₹400 Cr procurement). IndiaRF (Synthimed majority holder) considering stake reduction; company has tag-along rights but supply continuity at risk if stake sale disrupts relationship.

New market execution

Medium

8-9 new territories (Brazil, Mexico, Peru, Congo, Cambodia, Rwanda, Nigeria, Benin) in registration/early stage. Typical 1-1.5 years to first revenue; distributor partnerships, local compliance, market entry execution risk.

Management

Score 7/10. Clear on CDMO growth drivers and market strategy. Transparent on margin challenges (19-20% next quarter vs 22% target). Deferred capex details to ConfidLeap. Hedging on FY28 guidance revision (noted will increase). NDA-shields on some customer details (proprietary). Met FY27 >50% revenue growth (delivered 57.5%). CDMO ramp faster than expected (Q1 ₹15 Cr → Q2 ₹65 Cr). EBITDA margin target (18% sustainable, 21-22% H2) partially missed; Q2 17.97%, next quarter 19-20%. Track record: growth yes, margin execution weaker.

What to watch next
  • 1 · Q3 FY27

    Ibuprofen ramp to ₹20-25 Cr, Clarithromycin European site variation approval, Macrogol scaling

  • 2 · H2 FY27

    Samba facility EU-GMP/PIC/S ANVISA approval (Brazil focus), margin recovery to 19-20%+

  • 3 · 10-12 months

    Derassi warehouse shift completion for export capacity, ₹1,200 Cr revenue path by FY28

Near-term risk: margins compressed at 18.7% OPM vs 18% target, Q3-Q4 guidance 19-20% vs 22% internal target signals execution slippage despite strong top-line.

Informational and educational content only. Not investment advice.